High-throughput affinity-based technologies are rapidly growing in use as primary screening methods in drug discovery. In this review, their principles and applications are described and their impact on small-molecule drug discovery is evaluated. In general, these technologies can be divided into 2 groups: those that detect binding interactions by measuring changes to the protein target and those that detect bound compounds. Technologies detecting binding interactions by focusing on the protein have limited throughput but can reveal mechanistic information about the binding interaction; technologies detecting bound compounds have very high throughput, some even significantly higher than current high-throughput screening technologies, but offer limited information about the binding interaction. In addition, the appropriate use of affinity-based technologies is discussed. Finally, nanotechnology is predicted to generate a significant impact on the future of affinity-based technologies. (Journal of Biomolecular
INTRODUCTION
I n contemporary small-molecule drug discovery, the first step is to develop an understanding of the molecular pathways involved in a disease state, typically based on genetic analysis, and then to identify protein components of these pathways that can be pharmacologically modulated to alter the course of disease. Next, small-molecule compounds that can interact with the targets are discovered and optimized into drugs. Generally, high-throughput screening (HTS) is used to find small-molecule lead compounds. Various assay formats are used in HTS: in vitro assays using recombinant proteins such as enzyme assays and ligand competition assays as well as cell-based screens using reporter assays and cell-based secondmessenger assays (fluorometric imaging plate reader [FLIPR]). [1] [2] [3] In recent years, with the development of many new detection technologies, affinity-based methods have gained popularity in drug discovery.
Affinity-based technologies offer several unique advantages over traditional HTS assays that rely solely on the detection of the biochemical activity of the target. Because detection of small-molecule interactors using affinity-based technologies is only dependent on compound binding to protein targets, proteins of unknown function can be readily screened, and the resulting hits can be used for target validation in phenotypic cell-based assays. Thus, affinity-based screening can directly contribute to the advancement of chemical genomics, in which therapeutic targets are validated by monitoring cellular responses upon treatment with small-molecule compounds, before the direct biochemical function of a protein target is fully understood. 4, 5 Once a compound that was initially identified as a binder to a target is confirmed as active in a relevant cell-based assay, it can be progressed into further preclinical studies. As a result, phases that have been traditionally separated in drug discovery, target validation, and lead discovery can be merged to shorten drug discovery timelines. Another significant advantage of affinity-based technologies is the ability to screen targets for which the appropriate functional assays may be difficult to adapt to HTS. Furthermore, for many affinity-based technologies, it is very easy to multiplex compounds on a large scale, resulting in significant cost savings by eliminating the cost of HTS infrastructure, maintenance, and bulk reagents. Unlike ligand competition assays, which can only find compounds that bind to the active sites of protein targets, allosteric compounds can also be found in affinity-based assays. Finally, in many HTS assays, false positives or false negatives can result from assay interference due to fluorescence or colored compounds. However, these kinds of assay interference can be avoided using affinity-based assays.
In affinity-based assays, active compounds are identified as a consequence of binding interactions between protein targets and small-molecule compounds. Based on the detection principle used, affinity-based technologies can be divided into 2 groups: technologies that measure changes in the protein that occur upon binding to a small molecule or those that rely on the detection and identification of bound compounds. Detecting binding interactions by measuring changes associated with the protein typically can provide more information (kinetics, mechanism, etc.) of the binding interaction itself, but it is not designed to distinguish individual bound compounds from a mixture. Thus, only one compound can be studied per reaction mixture, which inherently limits the throughput of these technologies. Although methods that detect bound compounds do not typically provide much information on the mechanism of the binding interaction, many compounds can be mixed and individual bound compounds can be identified, resulting in much higher throughput. Common technologies in both approaches are discussed in this review. *
AFFINITY-BASED TECHNOLOGIES DETECTING BOUND PROTEIN

Optical sensing
A number of technologies to detect changes that occur upon the binding of small molecules to proteins have been developed based on optical sensing: surface plasmon resonance (SPR) 6, 7 and planar wave-guide. 8, 9 Target protein is immobilized onto a solid surface via covalent or noncovalent interaction. Binding of small-molecule compounds changes the refractive index of the immobilized target, which can be detected by optical sensing.
Biacore (Piscataway, NJ) has developed an SPR system by using a flow chamber 6 ; Corning (Corning, NY) and SRU (Woburn, MA) have developed planar wave-guide systems (Epic, BIND) by using microplates, resulting in increased throughput. 8, 9 Based upon data obtained by SPR, kinetic parameters and equilibrium constants of binding (i.e., on-rate, off-rate, and apparent dissociation constants) can be determined. 7, 10, 11 A recent study of carbonic anhydrase II that compared SPR with the traditional measurement of stopped-flow fluorescence showed that the kinetic parameters determined by SPR are in agreement with those determined by stopped-flow fluorescence. 12 In addition, by appropriate use of SPR data, agonists, antagonists, and irreversible inhibitors of estrogen receptor have been identified and differentiated. Effects of environmental factors (e.g., pH) on binding interaction can also be studied by SPR. 13 In another study of ITMN-191, a macrocyclic inhibitor of HCV NS3 protease, SPR data indicated that ITMN-191 and NS3 formed an initial collision complex and then isomerized into a highly stable complex with 62 pM affinity and a 5 hr halflife. 14 Therefore, it is an effective tool to study the mechanism of drug-protein interaction.
In addition to mechanism studies, drug screening by SPR also has been explored. In one example, based on a study of the binding mechanism between human serum albumin and warfarin, an SPR protocol was optimized for drug screening, and 10 compounds were tested to validate it. 13 However, due to its limited throughput, SPR has been mainly used for focus-deck screening or secondary confirmation screening. Screening of a small library of 47 compounds against a prion protein generated 6 hits that have shown activity in a cell-based assay. 15 Recently, SPR has also been applied to a novel drug discovery strategy, fragment-based drug design (FBDD). In FBDD, a diverse set of very small compounds (molecular weight <300) is tested by affinity-based methods. Because the potency of these small fragments is extremely low (high mM to mM), functional assay-based HTS with sensitivity in the range of nM to low mM generally cannot be used. Identified weak binders are used as fragments to build compounds with higher affinity and selectivity. As a result, a very diverse and vast chemical space can be explored with a relatively small number of compounds (1000-15,000). 16 In one study, a fragment library of 2226 compounds was screened against chymase (a serine protease) by SPR, resulting in 90 hits. Mechanistic studies showed that these fragment hits bind to different parts of the active site, so it might be possible to generate more potent compounds if different fragments could be combined properly. 17 In another study, a screen of a 245member fragment library against 3 variants of matrix metalloproteinase 12 (MMP-12) and a reference protein by SPR identified 11 fragments that specifically bind to MMP-12. Further study of kinetics and binding equilibrium identified 2 effective inhibitors (the most potent one with an IC 50 of 290 nM). 18 Although in both studies, no optimized compounds were made based on identified active fragments, these studies clearly demonstrated the feasibility of applying SPR to FBDD. Compared with nuclear magnetic resonance (NMR) and X-ray crystallography, which are commonly used in FBDD (discussed later), SPR consumes less enzyme and compound ( Table 1) , but it cannot offer direct structural information.
One major challenge for applying these optical sensing technologies to small-molecule drug discovery is the limit of detection. The change of refractive index depends on the molecular weight ratio of bound small-molecule compound to target protein. For proteins with high molecular weight, it may not be easy to detect bound compounds with very low molecular weight. Thus, although in many cases refractive index change *Recently, new approaches based on label-free detection technologies have gained interest in drug discovery. Because certain affinity-based technologies are label free, it is easy to confuse the two. However, some affinity-based technologies rely on labels (e.g., DNA tagged), and certain label-free technologies are not affinity based (cell-based impedance detection). The focus of this review is on affinity-based technologies, not label free. due to conformational change of protein upon binding to compounds has been a useful approach, it may not be broadly applicable to a wide range of targets.
Thermal shift
When protein is heated, it unfolds and loses its native conformation. Small-molecule binding can often stabilize the native conformation of a protein, resulting in a higher unfolding temperature. The shift in unfolding temperature can be detected using an environmentally sensitive fluorescent dye. A system developed using a plate format and a CCD camera was used for detection to increase the throughput (Thermo Fluor, 3DP, Morrisville, PA). 19 In another case, equipment used for quantitative PCR was converted for this purpose. 20 Because binding affinity is a function of both unfolding temperature change and enthalpy change, Kd cannot be determined based on thermal shift data alone. Additional experiments relying on isothermal titration calorimetry (ITC) are needed to determine enthalpy change upon binding to compounds, and then both data sets can be used to accurately determine the Kd. 20 However, because enthalpy change upon binding to compounds generally falls into a narrow range, a fixed value of enthalpy change can be used to approximately calculate Kd based on only thermal shift data. 21 Published data are available on more than 100 protein targets that have been tested using thermal shift assays. Among them are some common classes of therapeutic targets: nuclear hormone receptors, cytokine receptors, and integral membrane proteins. Dissociation constants of known inhibitors and lig ands for these targets determined by thermal shift assays correlated well with the published values. A screen of 7 focused libraries (665 compounds) generated 213 hits, and their Kd values showed good correlation, with the Ki values determined by an enzymatic assay. 19 In another study, 13 known inhibitors of b-site amyloid precursor protein-cleaving enzyme 1 were studied by both thermal shift assay and ITC, and the dissociation constants were found to be in good agreement for most compounds, except for a few weak binding inhibitors. Because DTm values are small for these weak binding inhibitors, the errors in the calculated binding constants are large. It was suggested that thermal shift assays should be conducted at a higher concentration for these compounds. 20 In recent years, very few studies based on thermal shift technology have been published. The technical difficulty of monitoring slight temperature changes (temperature fluctuation, well-to-well variation, etc.) is most likely a major factor limiting its application in small-molecule lead discovery.
NMR and X-ray crystallography
NMR and X-ray crystallography are powerful and mature technologies for studying interactions between small-molecule compounds and protein targets. With the integration of automated liquid handling, detection, and data processing, NMR and X-ray crystallography have developed into high-throughput affinity-based technologies. [22] [23] [24] [25] In high-throughput NMR, the binding interaction between small molecules and protein is commonly monitored by the chemical shift of the compound, although some other detection methods (saturation transfer difference, simple relaxation measurement, etc.) are also used. [26] [27] [28] In high-throughput X-ray crystallography, the difference of diffraction between protein-compound binding complex and protein alone is monitored. 24 Unlike other affinity-based technologies where only the binding interaction is detected, in NMR and X-ray crystallography, both the binding interaction and bound compounds can be detected. Thus, these methods allow a certain level of compound mixing, and generally pools of 5 to 100 compounds can be interrogated for binders. 29, 30 Because NMR and X-ray crystallography require larger amounts of protein and compounds and longer data acquisition time than other affinity-based technologies, only a limited number of compounds can tested. Despite this limitation, these technologies can detect weak binders in the mM affinity range. 29 We list parameters in some recent references as a guide for understanding affinity-based technologies. They represent the normal range of parameters in respective technologies.
The ability to detect weak interactions makes these technologies powerful tools for FBDD.
FBDD based on high-throughput NMR and X-ray crystallography has been successfully applied to many therapeutic targets. An initial screen of Bcl-2 (B-cell lymphoma) against a 10,000-compound fragment library (average MW: 210 Da) by high-throughput NMR yielded a biaryl acid hit with an affinity (Kd) of 300 mM. In a second screen against a 3500-compound fragment library (average MW: 125 Da), a variety of naphthol analogs and a biaryl phenol were identified with low affinity (2-13 mM) to a second site. By properly linking fragments to the 2 sites, a lead compound with Ki of 36 nM was obtained. 31 The utility of this technology has also been demonstrated with protein kinases, a major class of drug targets. Traditionally, drug discovery efforts have been focused on the adenosine triphosphate (ATP) binding pocket. In a recent study, starting from a screen of a diverse fragment library of 10,000 compounds against 3-phosphoinositide-dependent kinase-1 (PDK1) by NMR, several activators binding at an allosteric site were identified, and their activity was confirmed. 32 In another approach to FBDD using high-throughput X-ray crystallography, 2 fragment libraries of several hundred compounds were screened against p38a MAP kinase. Based on 2 initial hits (IC 50 : 1.3 mM and 35 mM), which bound at different sites on the protein, a lead compound was synthesized with an IC 50 of 0.17 mM in a cell-based assay. 33 Another recent successful application of this technology focused on b-secretase, an important target for Alzheimer's disease. Early efforts to discover inhibitors had focused on substrate-based peptides. However, it was very difficult to develop these peptides into drugs due to low oral bioavailability, poor blood-brain barrier permeability, and susceptibility to P-glycoprotein transport. 34 To find nonpeptide leads, which are different from the native substrate, FBDD by X-ray crystallography was used. An initial screen of 347 drug fragments identified 2 weak hits (30%-40% inhibition at 1 mM). After a virtual screen generated a list of 65 fragments, a second screen by X-ray crystallography discovered 3 hits with IC 50 values in the range of several hundred mM. Based on these fragment hits, a lead compound was generated with an IC 50 of 690 nM. 30, 35 Although the binding interaction between target proteins and compounds can be directly detected by NMR and X-ray crystallography, it requires a large amount of protein, which may be a limitation for using these tools with some targets ( Table 1) . Thus, the use of FBDD is also limited by the amount of protein that can be generated for a particular target. Furthermore, in FBDD, the identified binding fragments are only building blocks, and it is generally a lengthy and laborious procedure to combine the fragments into a potent and active compound. Another limitation for all affinity-based technologies detecting bound protein is that they all require purified proteins, and they are not compatible with cells, cell lysate, or membranes. Both limitations can be overcome using affinity-based technologies detecting bound compounds.
AFFINITY-BASED TECHNOLOGIES DETECTING BOUND COMPOUNDS
Mass spectrometry
Because compounds can be directly detected by mass spectrometry (MS) without additional tagging, it has been accepted as the detection method of choice for affinity selection by several pharmaceutical companies. [36] [37] [38] Generally, a separation step before MS detection is used to remove unbound compounds. The separation can be achieved by several means: affinity based, size exclusion, or ultrafiltration.
In frontal affinity chromatography with MS detection (FAC-MS), a target protein is immobilized to a solid support via an affinity tag. Compounds are bound to the target protein, and then unbound compounds are washed away. Finally, the bound compounds are specifically eluted. Typically, about 200 compounds can be loaded in each run. 39 In size exclusion separation, a size exclusion chromatography (SEC) column is used to separate bound from unbound compounds. Two technologies are well established for high-throughput SEC-MS: SpeedScreen (Novartis, Basel, Switzerland), which can handle 400 compounds per mixture, 36 and ALIS (Automated Ligand Identification System; Schering-Plough, Kenilworth, NJ), which can handle 2500 per mixture. 37 There are slight differences between the two technologies: spin columns in plate format are used in SpeedScreen versus an array of continuous-flow SEC columns used in ALIS; in addition, ion trap MS is used in SpeedScreen versus time-of-flight MS used in ALIS. 40 When ultrafiltration is used to separate bound from unbound compounds, throughput can be as high as 2700 compounds per mixture. 38 The approach of ultrafiltration coupled with MS has also been applied to identify active compounds from natural products, an approach overlooked by mainstream pharmaceutical research in recent years. 41 One of the reasons it has not gained general acceptance is due to concern that unbound compounds cannot be totally removed by ultrafiltration because a significant amount of residual volume remains after each round of selection.
All these technologies have been applied to many types of protein targets (enzymes, nuclear receptors, membrane receptors, etc.). ALIS was used to screen a multimillion compound library against b-secretase. A small compound (molecular weight [MW] = 506) was identified with an IC 50 of 25 mM. 42 In another application of ALIS in which 356,474 compounds were screened, both orthosteric and allosteric antagonists were discovered for muscarinic M2 acetylcholine receptor, a G-proteincoupled receptor. Their activity was confirmed in a biochemical assay. 43 MS has also been used for direct identification of bound small-molecule compounds without a prior separation step. 44 It was achieved by detection of a complex of compounds and target protein. Because unbound compounds were still in the mixture, it greatly limited the capability of multiplexing compounds (11 compounds) . Recently, this approach was applied to a screen of natural product extracts against bovine carbonic anhydrase II (bCAII). Because unbound compounds were still in the mixture and it was necessary for the protein to maintain its native conformation throughout the whole MS process to bind compounds, conditions had to be optimized using control compounds. A comparison study with a prior SEC isolation step showed only 60% of extracts could be detected by direct MS, whereas 100% could be detected by including a prior SEC step. 45 In another approach to MS detection without a prior separation step, hydrogen/deuterium (H/D) exchange of protein is measured. The rate of H/D exchange depends on the stability of the protein target. Because the binding of small-molecule compounds increases the stability of the protein target, it can have an effect on H/D exchange in the presence of a low concentration of denaturant. To identify hits with a wide range of binding affinities, several concentrations of denaturant have to be used, which slows down the throughput of this method. 46 Although all these approaches lacking a prior separation step can detect both bound compounds and binding interaction in one single step, they are still not mature enough for general use in drug discovery because currently only small pools of compounds can be tested, and a significant amount of optimization time is required for different targets. Nevertheless, with the advancement of MS technology, these limitations may be overcome in the future.
High-throughput MS-based affinity methods have become a powerful tool in small-molecule drug discovery. But even with a prior affinity selection step, multiplexing of compounds has to be capped at less than 3000 compounds per mixture due to the detection limit of MS. This barrier can be broken by DNAencoded technologies.
DNA encoding
With the advance of DNA and PCR-based technologies, DNA has moved beyond being only a subject of study to routine use in a wide variety of applications as a sensitive tag for the detection of a variety of biological molecules and small-molecule compounds. Use of DNA as a tag began with immuno-PCR, in which proteins are tagged with DNA, resulting in the ability to detect very low concentrations of protein by PCR. 47 For tagging small-molecule compounds, 4 approaches have been developed. In the first approach, nucleotides are first conjugated to small-molecule building blocks, which are then assembled into longer DNA oligonucleotides by DNA polymerase. Further chemical steps result in the synthesis of the building blocks into a complex compound. 48 In a second related approach, the DNA tags conjugated to small-molecule building blocks are ligated enzymatically, and then the reactions are carried out as in the first approach. 49, 50 Another method that has been used is to conjugate a small molecule to a single DNA strand and then to attach a second small molecule to the complementary strand. 51 A fourth method that has recently been reported starts with a piece of double-stranded DNA, called the "headpiece," with a covalently closed end containing a linker to which a small-molecule scaffold core is attached. Following addition of a small-molecule building block to the scaffold core, another DNA tag, which encodes the identity of the chemical building block, is ligated to the headpiece. This process is repeated for several cycles to produce very large combinatorial libraries of compounds that each contain unique DNA tags. 52, 53 The first two approaches are collectively described as template-directed synthesis, in which building blocks are first conjugated to nucleotides, DNA pieces, or a strand of DNA. This conjugation requirement significantly limits the number of building blocks that can be used and thus the diversity of the assembled library. Further problems can arise during library synthesis because some building blocks can cause steric and/or electrostatic hindrances to DNA polymerases or DNA ligase and result in the failure to create a DNA tag. So far, the size of libraries made by these two approaches has not been reported.
As for the third approach, it is limited to only 2 building blocks because DNA forms a stable duplex. A chemical library of 70,000 compounds has been made based on this approach, which is much smaller than most compound decks for HTS (~1,000,000 compounds). Although triplex and quadruplex DNA structures have been reported, [54] [55] [56] these structures are not easy to form, and decoding can be a complicated issue for these forms of DNA.
In the last approach to on-DNA library generation described above, chemical synthesis and DNA encoding are separated, which greatly expands the range of chemical reactions that can be used on-DNA and can result in very diverse chemical libraries. The library sizes that can be made by the last approach are limited only by the number of available building blocks with particular reactive groups and can be as large as 100,000,000 compounds, 52 2 orders of magnitude higher than the compound deck for traditional HTS. The diversity and size of these types of libraries will most likely increase the probability of finding hits for therapeutic targets.
For the separation or "selection" of bound from unbound compounds, affinity-based methods are generally used. It is very difficult to apply SEC-based methods due to the size of the DNA tags, but smaller tags may make this method more feasible for reduced complexity or fragment-based DNA libraries. It is also very critical to develop the right conditions (buffer, detergent, ionic strength, etc.) to keep the target protein in its native state and effectively wash away unbound compounds. Finally, it is also important to identify the optimal affinity matrix to immobilize the protein and capture the DNA-tagged small-molecule binders. The development of tools for highthroughput affinity purification of proteins has greatly expanded the number of options available to immobilize proteins with affinity tags, and a number of different conditions can be tested side by side to optimize selections for a given target. Furthermore, because these tools have also been designed to work with small volumes of concentrated protein, the amount of protein required for an individual selection experiment is in the low microgram range. The addition of cofactors, substrates, or known small-molecule binders to the selection buffers can shift the population of binders, either by altering the structure of the target or by direct competition, and thus can potentially provide some insight into the binding sites and mechanism of action of the tagged compounds.
Once bound compounds are recovered, DNA tags are generally amplified by PCR, followed by sequencing or microarraying for decoding. In comparison to microarrays, the new generation of sequencing technologies offers higher capacity, higher sensitivity, and higher fidelity. 57 In addition, for very large libraries (e.g., 100,000,000 compounds), it is impossible to make microarrays to match all sequences, but high-capacity sequencing of selection outputs can provide sufficient sampling to identify enriched binders. Advances in modern sequencing technologies have also spurred the advancement of data analysis tools that can rapidly read, quantitate, and translate the sequences back into the encoded small-molecule structures.
Currently, GlaxoSmithKline and Merck have adapted this technology in their lead discovery efforts, and Bristol-Myers Squibb has just recently announced its interest in this type of screening. [58] [59] [60] With this approach, libraries of billions of compounds can be generated and screened with a small amount of protein, which is far beyond the reach of conventional HTS. It offers the enticing possibility of exploring deeper into chemical space without the high cost of HTS infrastructure and large amounts of reagents. However, DNA tagging of small-molecule libraries often raises the concern that the tagging strategies may limit the diversity of library; also, due to the minute amounts of individual compound in DNA-tagged library, it is impossible to check the integrity of an individual compound once it has been selected. It is hoped that these concerns can be properly addressed with the advancement of on-DNA chemistry and improved selection methods, and until then, it will not completely replace conventional HTS but will offer a powerful alternative method to perform a primary affinity-based screen.
SUMMARY AND FUTURE PERSPECTIVES
In recent years, many affinity-based technologies have been developed to meet the needs and challenges of small-molecule drug discovery. Lead compounds discovered by these technologies are in various stages of drug development. Overall, affinity-based technologies have demonstrated their value by accelerating the rate of drug discovery and reducing costs. The number of compounds that can be screened using DNA encoding has already surpassed the limitations of current HTS with much higher throughput and significantly less protein consumed ( Table 1) . For targets of unknown function or for which the assay is not easily amenable to HTS, it is the only option to move projects forward. Even with targets of known function, affinity-based technologies can produce molecules with novel mechanisms of action. Further improvements in the sensitivity, accuracy, and throughput of all affinity-based technologies will dramatically improve the quality and increase the diversity of small-molecule hits, which can then be prioritized for further drug development.
In affinity-based technologies, the binding interaction between protein targets and small-molecule compounds is measured instead of biological function. So there is always a risk that identified binders will not have the desired activity, especially if the protein is unstable and the structure is compromised in any way during the affinity binding process. It is a major concern that limits the growth and acceptance of affinitybased technologies, but it can be addressed in two ways: (1) by assessing whether the target protein is active and in its native conformation during the affinity binding process and (2) by testing the compound hits identified from these affinity-based technologies in the appropriate activity assay. But for certain targets, affinity-based assays may not be possible or convenient due to challenges with purifying and maintaining a significant amount of the target protein in an active state. Therefore, we believe high-throughput affinity-based assays will not completely replace traditional HTS based on functional assays but rather will provide an effective complementary option.
With so many affinity-based technologies available, it is always a challenge to choose the right one. It is clear from this review that the decision should be based on the resources and needs of the drug discovery program. If the program is at the exploratory stage with no chemical lead compounds, technology detecting bound compounds is a good choice to quickly find multiple hits and initiate hit-to-lead chemistry, but if the program has multiple lead compounds and is in full development, technology detecting binding interactions is a good choice to assess the lead series and to help understand the binding mechanism and kinetics. By selecting appropriately, affinity-based technologies can significantly affect the pace of drug discovery and also provide a better understanding of the nature of the interaction between the small molecule and the target.
Recently nanotechnology has been introduced into life sciences. Experiments with a nanowire covalently linked to a tyrosine kinase demonstrated that this method can be used to detect the binding of known small-molecule inhibitors in a concentration-dependent manner by monitoring conductivity. 61 The study was done in a microfluidic device with highly sensitive detection capabilities. Due to the very small volumes required, this method could potentially generate considerable savings in protein and compound consumption. In addition, multiplexing target proteins and testing compounds become possible if arrays of these devices can be built. In another study, a nanoscale SPR chip was coupled with a nano-LC/MS to detect binding interactions and identify competing small molecules. Although it was designed to study competition binding, it is feasible to adapt it for direct binding studies. 62 On the basis of all of these new developments, we believe that as nanotechnology tools become more widespread, they will be applied to a new generation of affinity-based technologies. It is conceivable that nanotechnology tools will synergize with the many recent developments in affinity-based screening to create the next generation of powerful high-throughput tools for drug discovery capable of rapidly screening libraries many orders of magnitude larger than current screening collections, with lower protein requirements and higher success rates in delivering safe and efficacious compounds to the clinic.
